Moshe Oren

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9245937/publications.pdf

Version: 2024-02-01

129 papers	24,069 citations	9756 73 h-index	13338 130 g-index
135 all docs	135 docs citations	135 times ranked	24949 citing authors

#	Article	IF	Citations
1	Mdm2 promotes the rapid degradation of p53. Nature, 1997, 387, 296-299.	13.7	4,033
2	The first 30 years of p53: growing ever more complex. Nature Reviews Cancer, 2009, 9, 749-758.	12.8	1,684
3	Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature, 1984, 312, 646-649.	13.7	768
4	Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes and Cancer, 2011, 2, 466-474.	0.6	751
5	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	13.5	691
6	The p53â€"Mdm2 module and the ubiquitin system. Seminars in Cancer Biology, 2003, 13, 49-58.	4.3	665
7	Mutant p53 Gain-of-Function in Cancer. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001107-a001107.	2.3	621
8	ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes and Development, 2001, 15, 1067-1077.	2.7	550
9	Interaction of c-Abl and p73Î± and their collaboration to induce apoptosis. Nature, 1999, 399, 809-813.	13.7	529
10	Regulation of the p53 Tumor Suppressor Protein. Journal of Biological Chemistry, 1999, 274, 36031-36034.	1.6	499
11	Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene, 2002, 21, 1299-1303.	2.6	431
12	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 1999, 18, 477-485.	2.6	411
13	Mutant p53 Prolongs NF-Î⁰B Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer. Cancer Cell, 2013, 23, 634-646.	7.7	388
14	Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature, 1986, 320, 182-185.	13.7	369
15	Requirement of ATM-Dependent Monoubiquitylation of Histone H2B for Timely Repair of DNA Double-Strand Breaks. Molecular Cell, 2011, 41, 529-542.	4.5	347
16	Opposing Effects of Ras on p53. Cell, 2000, 103, 321-330.	13.5	346
17	Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nature Cell Biology, 2008, 10, 483-488.	4.6	333
18	Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature, 1996, 382, 816-818.	13.7	329

#	Article	IF	Citations
19	The p53 and Mdm2 families in cancer. Current Opinion in Genetics and Development, 2002, 12, 53-59.	1.5	271
20	A functional p53-responsive intronic promoter is contained within the humanmdm2gene. Nucleic Acids Research, 1995, 23, 2584-2592.	6.5	268
21	p53 and apoptosis. Seminars in Cancer Biology, 1998, 8, 359-368.	4.3	253
22	The Wip1 Phosphatase Acts as a Gatekeeper in the p53-Mdm2 Autoregulatory Loop. Cancer Cell, 2007, 12, 342-354.	7.7	246
23	A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes and Development, 2006, 20, 2687-2700.	2.7	245
24	The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes and Development, 2008, 22, 2664-2676.	2.7	240
25	Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53. Cancer Cell, 2010, 17, 273-285.	7.7	228
26	A single gene and a pseudogene for the cellular tumour antigen p53. Nature, 1983, 306, 594-597.	13.7	219
27	The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature, 2020, 586, 133-138.	13.7	216
28	p53: the ultimate tumor suppressor gene?. FASEB Journal, 1992, 6, 3169-3176.	0.2	215
29	Mdm2 Regulates p53 mRNA Translation through Inhibitory Interactions with Ribosomal Protein L26. Molecular Cell, 2008, 32, 180-189.	4.5	210
30	Down-Regulation of Î²-Catenin by Activated p53. Molecular and Cellular Biology, 2001, 21, 6768-6781.	1.1	203
31	Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. Journal of Biological Chemistry, 2002, 277, 18817-18826.	1.6	203
32	Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene, 1999, 18, 3205-3212.	2.6	189
33	RNF20 and USP44 Regulate Stem Cell Differentiation by Modulating H2B Monoubiquitylation. Molecular Cell, 2012, 46, 662-673.	4.5	187
34	p53 and ribosome biogenesis stress: The essentials. FEBS Letters, 2014, 588, 2571-2579.	1.3	181
35	Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1and results in apoptosis and tumor suppression. Nature Medicine, 1998, 4, 835-838.	15.2	179
36	The RING Domain of Mdm2 Mediates Histone Ubiquitylation and Transcriptional Repression. Molecular Cell, 2004, 16, 631-639.	4.5	178

#	Article	IF	Citations
37	Mutant p53 Enhances Nuclear Factor Î°B Activation by Tumor Necrosis Factor Î± in Cancer Cells. Cancer Research, 2007, 67, 2396-2401.	0.4	178
38	A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation. Molecular Cell, 2018, 71, 178-190.e8.	4.5	177
39	Mdm2: The Ups and Downs. Molecular Medicine, 1999, 5, 71-83.	1.9	176
40	Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20467-20472.	3.3	171
41	Physical and Functional Interaction between p53 and the Werner's Syndrome Protein. Journal of Biological Chemistry, 1999, 274, 29463-29469.	1.6	170
42	Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene, 2000, 19, 5944-5950.	2.6	165
43	The relationship between the nucleolus and cancer: Current evidence and emerging paradigms. Seminars in Cancer Biology, 2016, 37-38, 36-50.	4.3	149
44	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology, 2016, 151, 278-287.e6.	0.6	147
45	4sUDRB-seq: measuring genomewide transcriptional elongation rates and initiation frequencies within cells. Genome Biology, 2014, 15, R69.	3.8	146
46	CDK9 directs H2B monoubiquitination and controls replicationâ€dependent histone mRNA 3â€²â€end processing. EMBO Reports, 2009, 10, 894-900.	2.0	142
47	p53 Attenuates Cancer Cell Migration and Invasion through Repression of SDF-1/CXCL12 Expression in Stromal Fibroblasts. Cancer Research, 2006, 66, 10671-10676.	0.4	135
48	Caught in the cross fire: p53 in inflammation. Carcinogenesis, 2014, 35, 1680-1690.	1.3	123
49	p53 Mutations: Gains or losses?. Journal of Cellular Biochemistry, 1991, 45, 22-29.	1.2	122
50	Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function. Cancer Research, 2004, 64, 8318-8327.	0.4	122
51	Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4838-4843.	3.3	122
52	DNA Damage-induced Translocation of the Werner Helicase Is Regulated by Acetylation. Journal of Biological Chemistry, 2002, 277, 50934-50940.	1.6	121
53	Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis. Molecular Cell, 2012, 45, 222-232.	4.5	118
54	The loss of mdm2 induces p53 mediated apoptosis. Oncogene, 2000, 19, 1691-1697.	2.6	116

#	Article	IF	Citations
55	Writing and reading H2B monoubiquitylation. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2014, 1839, 694-701.	0.9	115
56	Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene, 2003, 22, 5667-5676.	2.6	111
57	Small Molecules Co-targeting CKIÎ± and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell, 2018, 175, 171-185.e25.	13.5	104
58	Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene, 1997, 15, 2717-2725.	2.6	102
59	New plays in the p53 theater. Current Opinion in Genetics and Development, 2011, 21, 86-92.	1.5	99
60	RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. Cell Reports, 2016, 14, 1462-1476.	2.9	99
61	Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene, 1998, 17, 1923-1930.	2.6	98
62	The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer and Metastasis Reviews, 1992, 11, 141-148.	2.7	94
63	Inhibition of p53 degradation by Mdm2 acetylation. FEBS Letters, 2004, 561, 195-201.	1.3	93
64	p53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner. Cancer Research, 2010, 70, 9650-9658.	0.4	93
65	Regulation of p53. Annals of the New York Academy of Sciences, 2002, 973, 374-383.	1.8	92
66	c-Abl Neutralizes the Inhibitory Effect of Mdm2 on p53. Journal of Biological Chemistry, 1999, 274, 8371-8374.	1.6	89
67	Downregulation of Î²-catenin by p53 involves changes in the rate of Î²-catenin phosphorylation and Axin dynamics. Oncogene, 2004, 23, 4444-4453.	2.6	89
68	RNF20 Inhibits TFIIS-Facilitated Transcriptional Elongation to Suppress Pro-oncogenic Gene Expression. Molecular Cell, 2011, 42, 477-488.	4.5	87
69	Systematic Identification of Proteins Binding to Chromatin-Embedded Ubiquitylated H2B Reveals Recruitment of SWI/SNF to Regulate Transcription. Cell Reports, 2013, 4, 601-608.	2.9	82
70	Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle, 2008, 7, 1870-1879.	1.3	81
71	Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6410-6415.	3.3	81
72	The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes and Development, 2016, 30, 786-797.	2.7	78

#	Article	IF	Citations
73	3â€™UTR Shortening Potentiates MicroRNA-Based Repression of Pro-differentiation Genes in Proliferating Human Cells. PLoS Genetics, 2016, 12, e1005879.	1.5	77
74	p53 Activation by Nitric Oxide Involves Down-regulation of Mdm2. Journal of Biological Chemistry, 2002, 277, 15697-15702.	1.6	76
75	Cotranscriptional histone H2B monoubiquitylation is tightly coupled with RNA polymerase II elongation rate. Genome Research, 2014, 24, 1572-1583.	2.4	74
76	Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene, 2018, 37, 1669-1684.	2.6	72
77	Involvement of p21WAF1/Cip1, CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition. Oncogene, 1997, 15, 1705-1711.	2.6	70
78	p53 shades of Hippo. Cell Death and Differentiation, 2018, 25, 81-92.	5.0	70
79	Cell Cycle Regulation and p53 Activation by Protein Phosphatase 2CÎ±. Journal of Biological Chemistry, 2003, 278, 14299-14305.	1.6	68
80	Down-regulation of LATS kinases alters p53 to promote cell migration. Genes and Development, 2015, 29, 2325-2330.	2.7	68
81	RNF20â€“RNF40: A ubiquitinâ€driven link between gene expression and the DNA damage response. FEBS Letters, 2011, 585, 2795-2802.	1.3	67
82	The Paradox of p53: What, How, and Why?. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026328.	2.9	65
83	Modulation of Mdm2 Expression and p53-Induced Apoptosis in Immortalized Human Ovarian Granulosa Cells**This work was supported by grants from the Israel Academy of Sciences (to I.V. and A.A.), by the Israeli Ministry of Science (to A.A.), by the Leo and Julia Forchheimer Center of Molecular Genetics at the Weizmann Institute of Science (to A.A.) and by a Grant-in-Aid 0704424 from the Ministry of Education, Science and Culture of Japan (to F.K., K.H., and A.A.).. Endocrinology, 1998, 139, 4688-4700.	1.4	61
84	New insights into YAP/TAZ nucleoâ€cytoplasmic shuttling: new cancer therapeutic opportunities?. Molecular Oncology, 2019, 13, 1335-1341.	2.1	61
85	Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E496-E505.	3.3	59
86	<i>TP53</i> missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	57
87	Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget, 2016, 7, 11817-11837.	0.8	56
88	microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network. Journal of Molecular Cell Biology, 2014, 6, 192-197.	1.5	54
89	The Werner syndrome protein contributes to induction of p53 by DNA damage. FASEB Journal, 2000, 14, 2138-2140.	0.2	49
90	The liverâ€specific microRNAâ€122*, the complementary strand of microRNAâ€122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. Hepatology, 2016, 64, 1623-1636.	3.6	48

#	Article	IF	Citations
91	p53 is essential for DNA methylation homeostasis in naÃ¯ve embryonic stem cells, and its loss promotes clonal heterogeneity. Genes and Development, 2017, 31, 959-972.	2.7	48
92	Regulation of p53 by Mdm2. Molecular Cell, 2004, 13, 4-5.	4.5	47
93	Nâ€Methylation of Isopeptide Bond as a Strategy to Resist Deubiquitinases. Angewandte Chemie - International Edition, 2012, 51, 11535-11539.	7.2	45
94	RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer. Cell Death and Differentiation, 2017, 24, 694-704.	5.0	44
95	Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure. Oncogene, 2000, 19, 3213-3215.	2.6	40
96	BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. Blood, 2006, 107, 1599-1607.	0.6	39
97	Involvement of stromal p53 in tumor-stroma interactions. Seminars in Cell and Developmental Biology, 2010, 21, 47-54.	2.3	38
98	Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. Cancer Research, 2019, 79, 760-772.	0.4	38
99	A Division of Labor between YAP and TAZ in Nonâ€"Small Cell Lung Cancer. Cancer Research, 2020, 80, 4145-4157.	0.4	38
100	ChIP-on-Chip Analysis of <i>In Vivo</i> Mutant p53 Binding To Selected Gene Promoters. OMICS A Journal of Integrative Biology, 2011, 15, 305-312.	1.0	36
101	PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma. Oncogene, 2018, 37, 2213-2224.	2.6	36
102	Simultaneous measurement of genome-wide transcription elongation speeds and rates of RNA polymerase II transition into active elongation with 4sUDRB-seq. Nature Protocols, 2015, 10, 605-618.	5.5	35
103	Repression of transposable-elements â€" a microRNA anti-cancer defense mechanism?. Trends in Genetics, 2010, 26, 253-259.	2.9	34
104	The majority of endogenous microRNA targets within Alu elements avoid the microRNA machinery. Bioinformatics, 2013, 29, 894-902.	1.8	30
105	The Hippo pathway, p53 and cholesterol. Cell Cycle, 2016, 15, 2248-2255.	1.3	26
106	LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state. Life Science Alliance, 2018, 1, e201800171.	1.3	26
107	Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin. Cancer Research, 2012, 72, 5824-5832.	0.4	25
108	TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma. Blood, 2018, 131, 2789-2802.	0.6	25

#	Article	IF	Citations
109	Targeting mutant p53 for cancer therapy. Aging, 2016, 8, 1159-1160.	1.4	24
110	Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone. Nucleic Acids Research, 2017, 45, 12681-12699.	6.5	21
111	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nature Communications, 2022, 13, 2800.	5.8	21
112	TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response. Cell Death and Differentiation, 2017, 24, 132-143.	5.0	16
113	Individual promoter and intron p53-binding motifs from the rat Cyclin G1 promoter region support transcriptional activation by p53 but do not show co-operative activation. FEBS Letters, 1998, 430, 171-175.	1.3	12
114	Teaming up to restrain cancer. Nature, 1998, 391, 233-234.	13.7	11
115	p53: not just a tumor suppressor. Journal of Molecular Cell Biology, 2019, 11, 539-543.	1.5	9
116	DePICTing p53 Activation: A New Nucleolar Link to Cancer. Cancer Cell, 2011, 20, 283-284.	7.7	8
117	Tumor Suppression by p53: Bring in the Hippo!. Cancer Cell, 2017, 32, 397-399.	7.7	8
118	Transcriptional profiling reveals a subset of human breast tumors that retain wt <i>TP53</i> but display mutant p53â€associated features. Molecular Oncology, 2020, 14, 1640-1652.	2.1	8
119	Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119644119.	3.3	8
120	p53 mutations promote proteasomal activity. Nature Cell Biology, 2016, 18, 833-835.	4.6	7
121	Pseudo-mutant P53 is a unique phenotype of <i>DNMT3A</i>-mutated pre-leukemia. Haematologica, 2022, 107, 2548-2561.	1.7	6
122	NFÎºB and p53: A life and death affair. Cell Cycle, 2010, 9, 1025-1030.	1.3	5
123	Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene, 2002, 21, 1299-1303.	2.6	5
124	Functional characterization of the p53 â€œmutomeâ€. Molecular and Cellular Oncology, 2018, 5, e1511207.	0.3	4
125	NFÎºB and p53: A life and death affair. Cell Cycle, 2010, 9, 1027.	1.3	4
126	BCL6 Is Regulated by p53 through a Response Element Frequently Disrupted in B-Cell Non-Hodgkinâ€™s Lymphoma.. Blood, 2005, 106, 158-158.	0.6	2

#	Article	IF	Citations
127	An Aurora A-Lats-Aurora B axis ensures proper chromosome segregation. Cell Cycle, 2011, 10, 3055-3055.	1.3	1
128	Repeated Application of Sequence-Specific SiRNA Molecules Leads to an Effective Downmodulation of All Clinically Relevant bcr-abl Gene Variants.. Blood, 2004, 104, 4319-4319.	0.6	1
129	Combination of Imatinib with Cisplatin and Nutlin-3: Functional and Molecular Effects on Bcr-Abl Positive Cells.. Blood, 2007, 110, 2954-2954.	0.6	0